Overview

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Status:
RECRUITING

Trial end date:
2026-08-04

Target enrollment:

Participant gender:

Summary

This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) administered to participants with progressive PSMA-positive metastatic castration-resistant prostate cancer. The study will also characterize the risk of QT prolongation of AAA617 in this participant population.

Phase:

PHASE2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

gallium 68 PSMA-11
Pluvicto